Log In
BCIQ
Print this Print this
 

JTX-2011

  Manage Alerts
Collapse Summary General Information
Company Jounce Therapeutics Inc.
DescriptionInducible T cell co-stimulator (ICOS) agonist antibody
Molecular Target Inducible T cell co-stimulator (ICOS)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I/II
Standard IndicationSolid tumors
Indication DetailsTreat advanced relapsed or refractory solid tumors
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$2,561.0M

$225.0M

$2,300.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/19/2016

$2,561.0M

$225.0M

$2,300.0M

Get a free BioCentury trial today